Fact check · Version 1 · Sources checked
“A compounded GHRP-6 product is FDA-approved.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.
- What this answer is based on
- This answer uses an official regulator record or a specific product label.
- Limits of this answer
- U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- Whether a specific product has an approval or another official status.
Sources for this fact check
Show 5 sources
01Bulk drug substances used in compounding under section 503AU.S. Food and Drug Administration · Regulatory · 202602503A Category 3 bulk drug substances nominated without adequate supportU.S. Food and Drug Administration · Regulatory · 202603Bulk drug substances that may present significant compounding safety risksU.S. Food and Drug Administration · Regulatory · 202604United Pharmacy warning letterU.S. Food and Drug Administration · Regulatory · 201905Human drug compounding: FDA questions and answersU.S. Food and Drug Administration · Regulatory · 2026
- Sources checked by
- Site editor · Editorial review